Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback